Natco said with this licence agreement it can manufacture and sell Molnupiravir capsules 200 mg for Indian market, which will be sold under brand name MOLNUNAT for treatment of COVID-19 infection in.
India logged 1,68,063 new coronavirus infections taking the total tally of Covid-19 cases to 3,58,75,790 which includes 4,461 cases of the Omicron variant. Over nine lakh beneficiaries received their third dose of the Covid vaccine on the first day of the drive to administer the 'Precaution Dose' to the healthcare workers, frontline workers and sixty plus individuals.
The Indian Council of Medical Research has decided against including antiviral drug Molnupiravir in its Clinical Management Protocol for Covid-19 over safety concerns.